TAVI global registry delivers 1st results | On Call

Wed, 10/03/2012 - 10:01am
Mass Device

Edwards Lifesciences' transcatheter aortic valve implantation systems proves effective in the 1st reports from a global registry of TAVI patients, but safety issues raise eyebrows.

MassDevice On Call

MASSDEVICE ON CALL — The 1st reports from a global registry comparing Edwards Lifesciences' (NYSE:EW) Sapien transcatheter aortic valve implantation systems against open surgery came with mixed results.

The Sapien TAVI device proved effective after 1 year, but in-hospital mortality proved a significant issue, affecting 10 of 91 patients, reported.

"These deaths were mostly related to access-site bleeding and other major life-threatening bleeding events like tamponade," investigator Dr. Danny Dvir told the news site. "I hope that this is related to a learning-curve issue and that when many of the sites gain more experience doing these procedures we will see better early results.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.